GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

PF-06767832   Click here for help

GtoPdb Ligand ID: 9228

Synonyms: PF-6767832 | PF06767832
Compound class: Synthetic organic
Comment: PF-06767832 (compound 38) is an orally bioavailable, positive allosteric modulator (PAM) selective for the M1 muscarinic acetylcholine receptor (CHRM1) [2]. It is one of the compounds claimed in patent WO2016009297 [1]. M1 receptor PAMs are being designed for their potential to provide novel therapies for the treatment of M1-mediated diseases and disorders such as Alzheimer's disease.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 112.58
Molecular weight 409.15
XLogP 3.05
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC1COCCC1NC(=O)c1ncc(c(c1)Cc1ccc(cc1)c1cscn1)C
Isomeric SMILES O[C@H]1COCC[C@@H]1NC(=O)c1ncc(c(c1)Cc1ccc(cc1)c1cscn1)C
InChI InChI=1S/C22H23N3O3S/c1-14-10-23-19(22(27)25-18-6-7-28-11-21(18)26)9-17(14)8-15-2-4-16(5-3-15)20-12-29-13-24-20/h2-5,9-10,12-13,18,21,26H,6-8,11H2,1H3,(H,25,27)/t18-,21-/m0/s1
InChI Key VVZZHFMLRHJXTO-RXVVDRJESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Brodney MA, Davoren JE, Garnsey MR, Zhang L, O'neil SV. (2016)
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators.
Patent number: WO2016009297. Assignee: Pfizer Inc.. Priority date: 18/07/2014. Publication date: 21/01/2016.
2. Davoren JE, Lee CW, Garnsey M, Brodney MA, Cordes J, Dlugolenski K, Edgerton JR, Harris AR, Helal CJ, Jenkinson S et al.. (2016)
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.
J Med Chem, 59 (13): 6313-28. [PMID:27275946]
3. Fisher A. (2000)
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Jpn J Pharmacol, 84 (2): 101-12. [PMID:11128032]
4. Khajehali E, Valant C, Jörg M, Tobin AB, Conn PJ, Lindsley CW, Sexton PM, Scammells PJ, Christopoulos A. (2018)
Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor.
Biochem Pharmacol, 154: 243-254. [PMID:29777683]
5. Walker LC, Campbell EJ, Huckstep KL, Chen NA, Langmead CJ, Lawrence AJ. (2022)
M1 muscarinic receptor activation decreases alcohol consumption via a reduction in consummatory behavior.
Pharmacol Res Perspect, 10 (1): e00907. [PMID:34962108]